The following is a summary of “Vancomycin-resistant Enterococcus (VRE) Pneumonia in a Patient With Advanced Chronic ...

Spero Therapeutics Inc. (SPRO) announced that phase 1 results indicated significant lung uptake of SPR719, with enhanced ...

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) ...

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments ...